Derval O'Carroll
Compliance Officer at INFLARX N.V.
Net worth: - $ as of 31/03/2024
Profile
Derval O'Carroll is currently the SVP, Head-Global Regulatory Affairs & Compliance at InflaRx NV.
Previously, she worked as the Senior Director-Regulatory Affairs at Travere Therapeutics, Inc. from 2015 to 2017.
She also held the position of Head-Regulatory Affairs at Amryt Pharma Holdings Ltd.
and Amryt Pharma Plc.
Ms. O'Carroll completed her graduate studies and earned an MBA from University College Dublin.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
INFLARX N.V.
-.--% | 31/12/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Derval O'Carroll active positions
| Companies | Position | Start |
|---|---|---|
| INFLARX N.V. | Compliance Officer | 01/01/2022 |
Former positions of Derval O'Carroll
| Companies | Position | End |
|---|---|---|
| TRAVERE THERAPEUTICS, INC. | General Counsel | 01/12/2017 |
| AMRYT PHARMA PLC | General Counsel | - |
Amryt Pharma Holdings Ltd.
 Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | General Counsel | - |
Training of Derval O'Carroll
| University College Dublin | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| TRAVERE THERAPEUTICS, INC. | Health Technology |
| INFLARX N.V. | Health Technology |
| Private companies | 2 |
|---|---|
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
Amryt Pharma Plc
 Amryt Pharma Plc Pharmaceuticals: MajorHealth Technology Amryt Pharma Plc operates as a holding company with interests in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The company was founded on July 17, 2019 and is headquartered in Dublin, Ireland. | Health Technology |
- Stock Market
- Insiders
- Derval O'Carroll
